Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov;6(11):2033-2043.
doi: 10.1002/sctm.17-0101. Epub 2017 Oct 10.

Concise Review: Tissue Engineering of Urinary Bladder; We Still Have a Long Way to Go?

Jan Adamowicz  1 , Marta Pokrywczynska  1 , Shane Vontelin Van Breda  2 , Tomasz Kloskowski  1 , Tomasz Drewa  1
Affiliations
Review

Concise Review: Tissue Engineering of Urinary Bladder; We Still Have a Long Way to Go?

Jan Adamowicz et al. Stem Cells Transl Med. 2017 Nov.

Abstract

Regenerative medicine is a new branch of medicine based on tissue engineering technology. This rapidly developing field of science offers revolutionary treatment strategy aimed at urinary bladder regeneration. Despite many promising announcements of experimental urinary bladder reconstruction, there has been a lack in commercialization of therapies based on current investigations. This is due to numerous obstacles that are slowly being identified and precisely overcome. The goal of this review is to present the current status of research on urinary bladder regeneration and highlight further challenges that need to be gradually addressed. We put an emphasis on expectations of urologists that are awaiting tissue engineering based solutions in clinical practice. This review also presents a detailed characteristic of obstacles on the road to successful urinary bladder regeneration from urological clinician perspective. A defined interdisciplinary approach might help to accelerate planning transitional research tissue engineering focused on urinary tracts. Stem Cells Translational Medicine 2017;6:2033-2043.

Keywords: Regeneration; Stem cells; Translational medicine; Urinary bladder; Urology.

PubMed Disclaimer

Conflict of interest statement

T.D. received honoraria as a Speaker for Astellas, Speaker for Bayer. The other authors indicated no potential conflicts of interest.

Figures

Figure 1
Figure 1
Indications for cystectomy with subsequently performed urine diversion comprise malignant and nonmalignant conditions. Invasive bladder cancer is the most common of them. Tissue engineering strategies included noncellular (A) and cellular (B) grafts, developed for bladder replacement.
Figure 2
Figure 2
Type of biomaterials used for urinary bladder regeneration in 141 patients. Indications for bladder reconstruction and applied material for augmentation among 141 cases does not indicate any variability of data. Abbreviations: BAM, bladder acellular matrix; BP, bovine pericardium; FPDB, formalin preserved dog bladder; GS, gelatin sponge; JP, Japanese paper; LHD, lyophilized human dura; PGA, polyglycoic acid; PLA, polylactic acid; PM, plastic mold; SIS, small intestinal submucosa.
Figure 3
Figure 3
Indications for urinary bladder reconstruction in 141 patients treated by tissue engineering methods. Indications for bladder reconstruction and applied material for augmentation among 141 cases does not indicate any variability of data.
See this image and copyright information in PMC

References

    1. Atala A, Bauer SB, Soker S et al.Tissue‐engineered autologous bladders for patients needing cystoplasty. Lancet 2006;15:1241–1246. - PubMed
    1. Dobruch J, Daneshmand S, Fisch M et al. Gender and bladder cancer: A collaborative review of etiology, biology, and outcomes. Eur Urol 2016;69:300–310. - PubMed
    1. Troussard G, Shariat SF, Dragomir A et al. Conditional survival after radical cystectomy for bladder cancer: Evidence for a patient changing risk profile over time. Eur Urol 2014;66:361–370. - PubMed
    1. Takenaka A. Current status of robot‐assisted radical cystectomy: What is the real benefit? Yonago Acta Med 2015;58:95–99. - PMC - PubMed
    1. Alfred Witjes J, Lebret T, Compérat EM et al. Updated 2016 EAU guidelines on muscle‐invasive and metastatic bladder cancer. Eur Urol 2017;71:462–475. - PubMed

LinkOut - more resources